Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer

BACKGROUNDS: Despite the clinical success of taxanes, they still have limitations, such as chemoresistance. To overcome the limitations of paclitaxel, genetic alterations and targeting effects of altered genes were observed in paclitaxel-resistant cancer. Because paclitaxel-resistant cancer shows hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Sol-Bi, Woo, Sang-Uk, Yim, Hyungshin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515847/
https://www.ncbi.nlm.nih.gov/pubmed/31156720
http://dx.doi.org/10.1177/1758835919846375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515847/
https://www.ncbi.nlm.nih.gov/pubmed/31156720
http://dx.doi.org/10.1177/1758835919846375

Ejemplares similares